Alterity Therapeutics Completes Securities Purchase Plan

TL;DR

**Alterity just raised capital through an SPP, boosting its cash for drug development.**

AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company, successfully completed its Securities Purchase Plan (SPP) on January 25, 2024. This plan, approved by shareholders at an Extraordinary General Meeting, allowed existing shareholders to purchase new shares, raising capital for the company. This matters to investors because it indicates the company has successfully secured additional funding, which can support its ongoing development of treatments for neurodegenerative diseases, potentially reducing the need for more dilutive financing in the short term.

Why It Matters

The successful completion of the SPP provides Alterity Therapeutics with additional capital, which is crucial for funding its research and development efforts in neurodegenerative diseases.

Risk Assessment

Risk Level: low — The successful completion of a capital raise generally reduces immediate financial risk for a company, providing funds for operations.

Analyst Insight

A smart investor would view this as a positive sign of financial stability and continued funding for R&D, potentially reducing near-term dilution risk. It would be wise to monitor how the company allocates these funds and the progress of their drug development pipeline.

Key Players & Entities

• Alterity Therapeutics Limited (company) — the registrant and biotechnology company
• Geoffrey P. Kempler (person) — Chairman of Alterity Therapeutics Limited
• February 2, 2024 (date) — date of the 6-K filing
• January 25, 2024 (date) — closing date of the Securities Purchase Plan

Forward-Looking Statements

• Alterity Therapeutics will use the capital raised from the SPP to advance its neurodegenerative disease treatments. (Alterity Therapeutics) — high confidence, target: 2024-12-31
• The successful SPP completion may reduce the immediate need for further dilutive financing. (Alterity Therapeutics) — medium confidence, target: 2024-06-30

FAQ

Filing Documents

• ea192693-6k_alterity.htm (6-K) — 14KB
• ea192693ex99-1_alterity.htm (EX-99.1) — 18KB
• image_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-009209.txt ( ) — 38KB

From the Filing

OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Successfully Completes Securities Purchase Plan SPP 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: February 2, 2024 2

View Full Filing

View this 6-K filing on SEC EDGAR